141 related articles for article (PubMed ID: 27378314)
1. First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males.
Moschetti V; Boland K; Feifel U; Hoch A; Zimdahl-Gelling H; Sand M
Br J Clin Pharmacol; 2016 Nov; 82(5):1315-1324. PubMed ID: 27378314
[TBL] [Abstract][Full Text] [Related]
2. A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers.
Boland K; Moschetti V; Dansirikul C; Pichereau S; Gheyle L; Runge F; Zimdahl-Gelling H; Sand M
Hum Psychopharmacol; 2017 Jan; 32(1):. PubMed ID: 28120486
[TBL] [Abstract][Full Text] [Related]
3. The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.
Moschetti V; Kim M; Sand M; Wunderlich G; Andersen G; Feifel U; Jang IJ; Timmer W; Rosenbrock H; Boland K
Eur Neuropsychopharmacol; 2018 May; 28(5):643-655. PubMed ID: 29567399
[TBL] [Abstract][Full Text] [Related]
4. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study.
Moschetti V; Desch M; Goetz S; Liesenfeld KH; Rosenbrock H; Kammerer KP; Wunderlich G; Wind S
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):239-249. PubMed ID: 29076028
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers.
Gale DD; Landells LJ; Spina D; Miller AJ; Smith K; Nichols T; Rotshteyn Y; Tonelli A; Lacouture P; Burch RM; Page CP; O'Connor BJ
Br J Clin Pharmacol; 2002 Nov; 54(5):478-84. PubMed ID: 12445026
[TBL] [Abstract][Full Text] [Related]
9. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers.
Zussman BD; Benincosa LJ; Webber DM; Clark DJ; Cowley H; Kelly J; Murdoch RD; Upward J; Wyld P; Port A; Fuder H
J Clin Pharmacol; 2001 Sep; 41(9):950-8. PubMed ID: 11549099
[TBL] [Abstract][Full Text] [Related]
10. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
11. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
Houghton LA; Atkinson W; Whorwell PJ; Morris J; Murdoch RD; Cooper SM; Webber DM; Walls CM
Clin Ther; 2006 Apr; 28(4):569-81. PubMed ID: 16750468
[TBL] [Abstract][Full Text] [Related]
12. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study.
Zhu X; Wu M; Wang H; Li H; Lin J; Peng Y; Hu Y; Li C; Ding Y
Expert Opin Investig Drugs; 2021 May; 30(5):579-589. PubMed ID: 33682556
[No Abstract] [Full Text] [Related]
14. Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.
Yamamoto T; Furihata K; Hisaka A; Moritoyo T; Ogoe K; Kusayama S; Motohashi K; Mori A; Iwatsubo T; Suzuki H
J Clin Pharmacol; 2017 Nov; 57(11):1491-1499. PubMed ID: 28679023
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.
Bogman K; Silkey M; Chan SP; Tomlinson B; Weber C
Eur J Clin Pharmacol; 2010 Oct; 66(10):1005-15. PubMed ID: 20549497
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality.
Nichols DJ; Muirhead GJ; Harness JA
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):5S-12S. PubMed ID: 11879254
[TBL] [Abstract][Full Text] [Related]
17. A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia.
Brown D; Daniels K; Pichereau S; Sand M
Neurol Ther; 2018 Jun; 7(1):129-139. PubMed ID: 29177699
[TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
Kim BH; Lim HS; Chung JY; Kim JR; Lim KS; Sohn DR; Cho JY; Yu KS; Shin SG; Paick JS; Jang IJ
Br J Clin Pharmacol; 2008 Jun; 65(6):848-54. PubMed ID: 18318773
[TBL] [Abstract][Full Text] [Related]
20. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
